Mainstay Medical International plc announced that Mr. Jason Hannon will succeed Mr. Peter Crosby as Chief Executive Officer with effect from October 9, 2017. Mr. Hannon's appointment results from the Company's succession planning associated with the retirement of Mr. Crosby at the end of October, 2017. Mr. Hannon will also be appointed as a Director with effect from October 9, 2017.

Mr. Hannon most recently served as President and Chief Operating Officer of NuVasive. His prior roles at NuVasive Inc. include Executive Vice President of International, Executive Vice President of Business Development and Strategy, and General Counsel. In the period up to his retirement date, Mr. Crosby will act as Special Adviser to the new CEO, and will continue to work with the Company as a consultant up to the end of 2020.

He will also continue to act as a Director until the conclusion of the Company's Annual General Meeting to be held on 22 September 2017, when he will retire as a Director. Mr. Crosby led Mainstay in its development of ReActiv8 from concept to commercialization.